Autoantibody development is associated with clinical severity of COVID-19: A cohort study

Marie Brinkmann; Ludwig Traby; Manuel Kussmann; Matthias Weiss-Tessbach; Nina Buchtele; Thomas Staudinger; Elias Gaidoschik; Thomas Perkmann; Helmuth Haslacher; Franz Ratzinger; Winfried F Pickl; Karim El-Gedawi; Melanie Feichter; Ellen Gelpi; Romana Höftberger; Peter Quehenberger; Rodrig Marculescu; Daniel Mrak; Kastriot Kastrati; Helga Lechner-Radner; Daniela Sieghart; Daniel Aletaha; Stefan Winkler; Michael Bonelli; Lisa Göschl

doi:10.1016/j.clim.2025.110471

Autoantibody development is associated with clinical severity of COVID-19: A cohort study

Marie Brinkmann, Ludwig Traby, Manuel Kussmann, Matthias Weiss-Tessbach, Nina Buchtele, Thomas Staudinger, Elias Gaidoschik, Thomas Perkmann, Helmuth Haslacher, Franz Ratzinger, Winfried F Pickl, Karim El-Gedawi, Melanie Feichter, Ellen Gelpi, Romana Höftberger, Peter Quehenberger, Rodrig Marculescu, Daniel Mrak, Kastriot Kastrati, Helga Lechner-RadnerDaniela Sieghart, Daniel Aletaha, Stefan Winkler, Michael Bonelli, Lisa Göschl

Scientific Working Group Allergology and Immunology

Research output: Journal article (peer-reviewed) › Journal article

Abstract

Viral infections, including respiratory diseases such as Coronavirus disease 2019 (COVID-19), are hypothesized to contribute to the onset of autoimmune disorders. Although elevated levels of autoantibodies have been observed following COVID-19, the role of specific autoantibodies linked to autoimmune diseases and their correlation with disease severity remains poorly defined. In this study, we used a comprehensive autoantibody panel to assess the autoantibody production across different cohorts of COVID-19 patients, categorized by disease severity. We also compared patients with severe COVID-19 to a control group with other severe, non-COVID-related diseases. Our findings indicate that the severity of COVID-19 corresponds to the overall production of specific autoantibodies, which are particularly associated with COVID-19. This association might predispose to an increased risk for the development of autoimmune conditions after a severe course of COVID-19.

Original language	English
Article number	110471
Pages (from-to)	110471
Journal	Clinical Immunology
Volume	274
DOIs	https://doi.org/10.1016/j.clim.2025.110471
Publication status	E-pub ahead of print - 03 Mar 2025

Access to Document

10.1016/j.clim.2025.110471

Cite this

Brinkmann, M., Traby, L., Kussmann, M., Weiss-Tessbach, M., Buchtele, N., Staudinger, T., Gaidoschik, E., Perkmann, T., Haslacher, H., Ratzinger, F., Pickl, W. F., El-Gedawi, K., Feichter, M., Gelpi, E., Höftberger, R., Quehenberger, P., Marculescu, R., Mrak, D., Kastrati, K., ... Göschl, L. (2025). Autoantibody development is associated with clinical severity of COVID-19: A cohort study. Clinical Immunology, 274, 110471. Article 110471. Advance online publication. https://doi.org/10.1016/j.clim.2025.110471

@article{87d774cae4364456a30b05a51032e99f,

title = "Autoantibody development is associated with clinical severity of COVID-19: A cohort study",

abstract = "Viral infections, including respiratory diseases such as Coronavirus disease 2019 (COVID-19), are hypothesized to contribute to the onset of autoimmune disorders. Although elevated levels of autoantibodies have been observed following COVID-19, the role of specific autoantibodies linked to autoimmune diseases and their correlation with disease severity remains poorly defined. In this study, we used a comprehensive autoantibody panel to assess the autoantibody production across different cohorts of COVID-19 patients, categorized by disease severity. We also compared patients with severe COVID-19 to a control group with other severe, non-COVID-related diseases. Our findings indicate that the severity of COVID-19 corresponds to the overall production of specific autoantibodies, which are particularly associated with COVID-19. This association might predispose to an increased risk for the development of autoimmune conditions after a severe course of COVID-19.",

author = "Marie Brinkmann and Ludwig Traby and Manuel Kussmann and Matthias Weiss-Tessbach and Nina Buchtele and Thomas Staudinger and Elias Gaidoschik and Thomas Perkmann and Helmuth Haslacher and Franz Ratzinger and Pickl, {Winfried F} and Karim El-Gedawi and Melanie Feichter and Ellen Gelpi and Romana H{\"o}ftberger and Peter Quehenberger and Rodrig Marculescu and Daniel Mrak and Kastriot Kastrati and Helga Lechner-Radner and Daniela Sieghart and Daniel Aletaha and Stefan Winkler and Michael Bonelli and Lisa G{\"o}schl",

note = "Publisher Copyright: {\textcopyright} 2024",

year = "2025",

month = mar,

day = "3",

doi = "10.1016/j.clim.2025.110471",

language = "English",

volume = "274",

pages = "110471",

journal = "Clinical Immunology",

issn = "1521-6616",

publisher = "Academic Press Inc.",

}

Brinkmann, M, Traby, L, Kussmann, M, Weiss-Tessbach, M, Buchtele, N, Staudinger, T, Gaidoschik, E, Perkmann, T, Haslacher, H, Ratzinger, F, Pickl, WF, El-Gedawi, K, Feichter, M, Gelpi, E, Höftberger, R, Quehenberger, P, Marculescu, R, Mrak, D, Kastrati, K, Lechner-Radner, H, Sieghart, D, Aletaha, D, Winkler, S, Bonelli, M & Göschl, L 2025, 'Autoantibody development is associated with clinical severity of COVID-19: A cohort study', Clinical Immunology, vol. 274, 110471, pp. 110471. https://doi.org/10.1016/j.clim.2025.110471

TY - JOUR

T1 - Autoantibody development is associated with clinical severity of COVID-19

T2 - A cohort study

AU - Brinkmann, Marie

AU - Traby, Ludwig

AU - Kussmann, Manuel

AU - Weiss-Tessbach, Matthias

AU - Buchtele, Nina

AU - Staudinger, Thomas

AU - Gaidoschik, Elias

AU - Perkmann, Thomas

AU - Haslacher, Helmuth

AU - Ratzinger, Franz

AU - Pickl, Winfried F

AU - El-Gedawi, Karim

AU - Feichter, Melanie

AU - Gelpi, Ellen

AU - Höftberger, Romana

AU - Quehenberger, Peter

AU - Marculescu, Rodrig

AU - Mrak, Daniel

AU - Kastrati, Kastriot

AU - Lechner-Radner, Helga

AU - Sieghart, Daniela

AU - Aletaha, Daniel

AU - Winkler, Stefan

AU - Bonelli, Michael

AU - Göschl, Lisa

PY - 2025/3/3

Y1 - 2025/3/3

N2 - Viral infections, including respiratory diseases such as Coronavirus disease 2019 (COVID-19), are hypothesized to contribute to the onset of autoimmune disorders. Although elevated levels of autoantibodies have been observed following COVID-19, the role of specific autoantibodies linked to autoimmune diseases and their correlation with disease severity remains poorly defined. In this study, we used a comprehensive autoantibody panel to assess the autoantibody production across different cohorts of COVID-19 patients, categorized by disease severity. We also compared patients with severe COVID-19 to a control group with other severe, non-COVID-related diseases. Our findings indicate that the severity of COVID-19 corresponds to the overall production of specific autoantibodies, which are particularly associated with COVID-19. This association might predispose to an increased risk for the development of autoimmune conditions after a severe course of COVID-19.

AB - Viral infections, including respiratory diseases such as Coronavirus disease 2019 (COVID-19), are hypothesized to contribute to the onset of autoimmune disorders. Although elevated levels of autoantibodies have been observed following COVID-19, the role of specific autoantibodies linked to autoimmune diseases and their correlation with disease severity remains poorly defined. In this study, we used a comprehensive autoantibody panel to assess the autoantibody production across different cohorts of COVID-19 patients, categorized by disease severity. We also compared patients with severe COVID-19 to a control group with other severe, non-COVID-related diseases. Our findings indicate that the severity of COVID-19 corresponds to the overall production of specific autoantibodies, which are particularly associated with COVID-19. This association might predispose to an increased risk for the development of autoimmune conditions after a severe course of COVID-19.

UR - http://www.scopus.com/inward/record.url?scp=85219238361&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2025.110471

DO - 10.1016/j.clim.2025.110471

M3 - Journal article

C2 - 40044018

SN - 1521-6616

VL - 274

SP - 110471

JO - Clinical Immunology

JF - Clinical Immunology

M1 - 110471

ER -

Autoantibody development is associated with clinical severity of COVID-19: A cohort study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this